Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Senate committee hears emotional appeals for LC 100 to eliminate follow‑up costs after abnormal cervical screenings
Summary
Lawmakers heard survivors, clinicians and advocates urge the Senate Interim Committee on Health to pass LC 100, a legislative concept to require commercial insurers to cover medically necessary follow‑up cervical diagnostic tests (colposcopy, biopsy, HPV typing) without cost sharing, after testimony about delayed care, racial disparities and average out‑of‑pocket follow‑up costs of $700–$1,000.
Representative Vanessa Hartman, who said she is currently being treated for stage‑3 cervical cancer, urged the Senate Interim Committee on Health to support LC 100 and described how cost barriers and lack of affordable follow‑up testing leave some patients unable to progress from screening to diagnosis and treatment. "Screening without affordable follow‑up is not prevention," Hartman said, recounting a constituent who was charged about $1,000 for a medically necessary colposcopy and could not afford it.
Jane Leo, Government Relations Director for the American Cancer Society Cancer Action Network in Oregon, told the committee follow‑up diagnostic costs commonly range from about $700 to more than $1,000…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
